You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 3, March 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, SAN FRANCISCO, CALIF, MAY 21 TO MAY 24, 1989-PAR T II
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Tumor Immunization

Improved Results After Vaccine Modified With Recombinant Interferon Gamma

Robert K. Sigal, MD; Michael D. Lieberman, MD; John V. Reynolds, FRCS; Noel Williams, FRCS; Moritz M. Ziegler, MD; John M. Daly, MD

Arch Surg. 1990;125(3):308-312.


Abstract

•The purpose of this study was to determine if a 3-day in vitro culture of the murine neuroblastoma C1300 with 500 U/mL of recombinant interferon gamma resulted in a protective crossreactivity to parent C1300. Twenty A/J mice received either a vaccine of 1 x 106 irradiated C1300 tumor cells intradermally or an equivalent innoculum of C1300 that had been incubated in recombinant interferon gamma (C1300*). One week later, all animals were rechallenged with 1 x 106 viable C1300. Animals immunized with C1300* had a significantly delayed early tumor incidence that translated into a survival advantage for the group. At the time of tumor rechallenge, a significantly increased level of nonspecific systemic immunity was conferred by the C1300* immunization. Thus, modification of tumor with recombinant interferon gamma before introduction as a vaccine may improve that vaccine's protective capability.

(Arch Surg. 1990;125:308-312)



Author Affiliations

From the Harrison Department of Surgical Research, the University of Pennsylvania School of Medicine, Philadelphia (Drs Sigal, Lieberman, Reynolds, Williams, and Daly) and the Joseph Stokes Jr Research Institute, the Childrens Hospital of Philadelphia (Dr Ziegler). Dr Reynolds is now with the Hull (England) Royal Infirmary.


Footnotes

Accepted for publication December 4, 1989.

Read before the annual meeting of the Society of Surgical Oncology, May 22, 1989, San Francisco, Calif.

Reprint requests to the Division of Surgical Oncology, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104 (Dr Daly).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.